Skip to content
live
live

Canada missed chance to help homegrown vaccines move quickly last spring: developers

The CEO of Entos Pharmaceuticals says funding was simply not offered to Canadian companies like it was in other parts of the world.
2021022212020-6033e3c022091910390f4b0bjpeg

Two vaccine developers in Canada say a lack of federal funding early in the pandemic kept homegrown vaccines from moving as quickly as international versions.

John Lewis, the CEO of Entos Pharmaceuticals in Alberta, says his company is one of six that received about $5 million to move their COVID-19 vaccine along.

But Lewis says other countries invested more than $300 million per company to ensure they had funding to get through the entire vaccine development process.

He says those companies, such as AstraZeneca and Pfizer, now have vaccines approved in dozens of countries.

Speaking to the House of Commons health committee today, Lewis says Canada still has no vaccine through the finish line.

Dr. Gary Kobinger, a microbiologist at Laval University who was part of Canadian teams that helped develop vaccines for Ebola and Zika, says his non-profit had a vaccine with excellent early lab results last February, but it stalled because "we couldn't find funding."

Rogers Media
2001 Thurston Drive Ottawa, ON, K1G 6C9 © 2006-2021 Rogers Media. All rights reserved.